First Trust Advisors LP acquired a new stake in shares of Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 90,926 shares of the biopharmaceutical company’s stock, valued at approximately $1,305,000. First Trust Advisors LP owned 0.09% of Lexicon Pharmaceuticals at the end of the most recent reporting period.
A number of other institutional investors have also recently made changes to their positions in LXRX. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp bought a new position in Lexicon Pharmaceuticals during the second quarter worth approximately $195,000. Quantbot Technologies LP raised its stake in Lexicon Pharmaceuticals by 12.3% in the second quarter. Quantbot Technologies LP now owns 13,999 shares of the biopharmaceutical company’s stock valued at $200,000 after buying an additional 1,529 shares in the last quarter. Acrospire Investment Management LLC acquired a new stake in Lexicon Pharmaceuticals during the first quarter valued at about $211,000. Old Mutual Global Investors UK Ltd. acquired a new stake in Lexicon Pharmaceuticals during the second quarter valued at about $257,000. Finally, Fox Run Management L.L.C. acquired a new stake in Lexicon Pharmaceuticals during the second quarter valued at about $274,000.
Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) traded up 0.95% during midday trading on Friday, reaching $18.07. The company’s stock had a trading volume of 465,745 shares. The firm’s market cap is $1.88 billion. Lexicon Pharmaceuticals Inc. has a one year low of $7.65 and a one year high of $19.62. The firm has a 50 day moving average price of $16.59 and a 200 day moving average price of $14.57.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.04. The firm earned $20.10 million during the quarter, compared to analyst estimates of $12.36 million. Lexicon Pharmaceuticals had a negative return on equity of 9.03% and a negative net margin of 13.42%. Lexicon Pharmaceuticals’s revenue was up 5186.8% on a year-over-year basis. During the same period in the prior year, the business posted ($0.27) EPS. Equities research analysts forecast that Lexicon Pharmaceuticals Inc. will post ($1.54) EPS for the current fiscal year.
Several equities research analysts recently issued reports on LXRX shares. Citigroup Inc. started coverage on Lexicon Pharmaceuticals in a research note on Tuesday, August 2nd. They set a “buy” rating and a $21.00 price objective for the company. Stifel Nicolaus lifted their price objective on Lexicon Pharmaceuticals from $25.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, August 5th. Needham & Company LLC reissued a “buy” rating and set a $21.00 price objective on shares of Lexicon Pharmaceuticals in a research note on Monday, September 12th. Wedbush reissued a “buy” rating and set a $33.00 price objective on shares of Lexicon Pharmaceuticals in a research note on Sunday, September 11th. Finally, Zacks Investment Research raised Lexicon Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 3rd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $22.17.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc (Lexicon) is a biopharmaceutical company. The Company focuses on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company’s telotristat etiprate, is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome.
Want to see what other hedge funds are holding LXRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX).
Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.